Breaking News

Tweet TWEET

Innovative Product Portfolios Ride Commercialization & Global Expansion - Research Report on Amgen, Onyx Pharmaceuticals,

  Innovative Product Portfolios Ride Commercialization & Global Expansion -
   Research Report on Amgen, Onyx Pharmaceuticals, Alexion Pharmaceuticals,
                      BioMarin Pharmaceutical and Incyte

PR Newswire

NEW YORK, March 18, 2013

NEW YORK, March 18, 2013 /PRNewswire/ --

Today, Wall Street Source announced new research reports highlighting Amgen
Inc. (NASDAQ: AMGN), Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX), Alexion
Pharmaceuticals, Inc. (NASDAQ: ALXN), BioMarin Pharmaceutical Inc. (NASDAQ:
BMRN) and Incyte Corporation (NASDAQ: INCY). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Amgen Inc. Research Report

As one of the most consistently traded stocks among biotechnology companies,
Amgen has been strategically outlining and delivering its approach to
long-term growth and profitability. Aside from improving shareholder value,
Amgen is committed to discovering, innovating, developing and manufacturing
breakthrough treatments for unheeded illnesses. Amgen is capitalizing on
major advances in drug discovery and biologics manufacturing as it boosts its
product pipeline. The company reported that one of its key strategies for
growth and profitability is international expansion and commercialization.
Amgen is expected to penetrate new and emerging markets as it expands its
access and value to payers or end-users. The Full Research Report on Amgen
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:
[http://www.WallStSource.com/r/full_research_report/e763_AMGN]

--

Onyx Pharmaceuticals, Inc. Research Report

With a vision to grow from a company with three therapies and four indications
to an industry leader, Onyx Pharmaceuticals is gearing up its operations as it
aims to reach more patients globally. The strong growth of Onyx
Pharmaceuticals last year was a solid basis for the company's near-term
momentum for sustainability. Investors are bullish that the company can
achieve its goals as it continues to rake in revenues and royalties amid its
expansion. Onyx Pharmaceuticals is preparing for US commercialization as it
scouts for opportunities in the international market. The Full Research Report
on Onyx Pharmaceuticals, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.WallStSource.com/r/full_research_report/fcf8_ONXX]

--

Alexion Pharmaceuticals, Inc. Research Report

Being the second most innovative company in Forbes' annual ranking, analysts
and investors are optimistic about the future of Alexion Pharmaceuticals as it
continues to advance its nine lead development programs for Soliris and four
additional innovative therapeutics. Alexion Pharmaceuticals continues to see
steady growth for Soliris as it continues the global commercialization of the
drug. The company is keen on expanding its global presence amid Soliris'
approval for patients with paroxysmal nocturnal hemoglobinuria (PNH) in US,
European Union and Japan. Alexion Pharmaceuticals also acquired the rights for
the first potential treatment for hypophosphatasia (HPP), and is currently
advancing the first-in-class targeted enzyme replacement therapy to Phase II
clinical trials. The Full Research Report on Alexion Pharmaceuticals, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.WallStSource.com/r/full_research_report/451f_ALXN]

--

BioMarin Pharmaceutical Inc. Research Report

With increased efforts for research and development, BioMarin Pharmaceuticals
is growing its business by boosting its commercial portfolio. BioMarin
Pharmaceuticals' product pipeline has helped the company surpass its $500
million revenue. The company believes that its portfolio will continue to
propel the company while improving shareholder value. BioMarin
Pharmaceuticals' reported that it expects to receive the first regulatory
approval for Vimizim by the end of this year. The Full Research Report on
BioMarin Pharmaceutical Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.WallStSource.com/r/full_research_report/936c_BMRN]

--

Incyte Corporation Research Report

The quarter-over-quarter growth of Incyte last year highlights the company's
growth potential as it continues to deploy its financial strategies. Incyte is
expecting an increase in research and development as the company partners with
Lilly for the Phase III study of baricitinib. In a 2013 financial guidance
report, Incyte also highlighted its $66 million milestone payment for Jakafi
under the Novartis and Lilly collaborative agreements. Analysts and investors
have high hopes in the company as it possesses growth potential in the
international market. The Full Research Report on Incyte Corporation -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.WallStSource.com/r/full_research_report/0762_INCY]

--

Consider Wall Street Source

Tired of hearing about the latest, greatest trade opportunity... only to
realize that the ship has long sailed? You need a strong, informative
community in your arsenal. Join the group that has been consistently
identifying momentous situations as they develop - long before they become the
next top news on major financial networks.

Contact: Joe Thomas
Email: press@wallstsource.com
Main: +1-310-496-8071 (North America)

SOURCE Wall Street Source